BSG and glioblastoma: In the case of MCT/BSG inhibition, recent work shows that blocking both MCT1 and MCT4 in human colon adenocarcinoma, glioblastomas and non-small cell lung carcinoma cells causes a shift of their metabolism from glycolysis to OXPHOS, which sensitise them to biguanides, such as metformin and phenformin [134, 14].